Cooperative Agreement UH3HL152381
- This Project Grant award of $623,433 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to Oregon Health & Science University (OHSU). The purpose of the grant is to adapt and implement Community Vital Signs (CVS) strategies to increase rates of blood pressure screening and connections to care for hypertension in Nigeria. The key products/services to be delivered through this 4-year project include: 1) Engaging...
- This federal Project Grant award of $708,678, provided by the National Heart, Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to conduct a Sequential Multiple Assignment Randomized Trial (SMART) to reduce food insecurity and improve adherence in patients with hypertension. The key products and services to be delivered under this grant include: Determining the most effective initial food insecurity intervention (resource information or community health worker...
- This Project Grant award from the U.S. Department of Health and Human Services' National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $1,072,621 to Duke University to conduct an adequately powered randomized controlled trial of a multi-component lifestyle intervention aimed at improving blood pressure control and cardiovascular outcomes in Black adults with chronic kidney disease (CKD). The goal is to evaluate the impact of lifestyle modifications,...
- The Project Grant award of $692,846.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) will fund the "Better Heart Study" at the University of Pennsylvania. The study aims to utilize behavioral science strategies to increase hypertension diagnosis and treatment in India, where hypertension prevalence remains high and many individuals are undiagnosed or not receiving care. The project will test two scalable behavioral...
- This federal Project Grant award of $130,065 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to conduct systematic economic analyses on the costs associated with implementing a chronic care model for patients with hypertension. The grant supports a study led by principal investigator Dr. Elaine Khoong and collaborators Dr. Dhruv Kazi, Dr. Lina Tieu, and Dr. Lisa Ochoa-Frongia. The project aims to...
- This $2,979,575 Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) will fund the "FIM+DASH: A Randomized Food Is Medicine Trial to Promote Healthy Eating and Blood Pressure Control in Hypertensive Black Women with Obesity" research project. The 4-year study, which begins on September 14, 2025, will be conducted by the University of Illinois in Chicago. The project aims to evaluate the...
- The National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), awarded a $688,525 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Diego (UCSD). The grant, titled "Blood Pressure Control Advancing Refugee Health Equity (BPCARE): An RCT of Adherence", aims to develop and test a behavioral intervention to improve antihypertensive medication adherence and blood pressure...
- This $631,589 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) will examine the implementation, effectiveness, and cost-effectiveness of two strategies for integrating a community health worker-facilitated hypertension telehealth intervention into primary health centers in Kenya. The goal is to address multi-level barriers to effective hypertension treatment and management. The two implementation approaches are:...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $793,184 to Northwestern University to conduct a 2x2 factorial randomized controlled trial. The trial will evaluate the effects of 1) automated transmission of home blood pressure values versus manual transmission, and 2) automatically-generated medical advice to patients via their patient portal versus no automated feedback. The primary outcome is...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $494,283 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Botswana (UB) to develop and test new strategies to initiate statin therapy for people living with HIV (PWH) who also have hypertension in Botswana. The project, titled "Integrating Hypertension and Cardiovascular Disease Care into Existing HIV Service Package in Botswana (INTERCARE)-Statin Sub-Study," will leverage...
EVALUATING THE IMPLEMENTATION AND SCALE-UP OF NIGERIA NATIONAL SODIUM REDUCTION PROGRAM - PROJECT ABSTRACT THE NIGERIAN AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL (NAFDAC) IS LEADING IMPLEMENTATION AND SCALE-UP OF A NATIONAL SODIUM REDUCTION PROGRAM WITH OTHER NATIONAL, STATE, AND INTERNATIONAL AGENCIES USING THE WHO'S "BEST BUY" SHAKE PACKAGE (SURVEILLANCE OF SALT INTAKE, HARNESS INDUSTRY, ADOPT STANDARDS FOR LABELLING AND MARKETING, KNOWLEDGE TO EMPOWER CONSUMERS, AND ENVIRONMENTS TO PROMOTE HEALTHY EATING). SHAKE PROVIDES EVIDENCE-BASED RECOMMENDATIONS FOR POPULATION-WIDE SODIUM REDUCTION INTERVENTIONS FOR HYPERTENSION PREVENTION AND CONTROL. OUR RESEARCH WILL SUPPORT AND EMBED IN THIS PROGRAM'S IMPLEMENTATION AND SCALE-UP FOR LATE-STAGE IMPLEMENTATION RESEARCH FOR HYPERTENSION PREVENTION AND CONTROL BY EVALUATING THE EXTENT TO WHICH THE PROGRAM IS IMPLEMENTED USING A TYPE III HYBRID, MIXED METHODS STUDY DESIGN THROUGH REPEATED: 1) STAKEHOLDER INTERVIEWS, 2) POPULATIONS SURVEYS, AND 3) RETAIL SURVEYS. WE WILL USE IMPLEMENTATION RESEARCH METHODS DURING ADAPTATION, PLANNING, AND INITIAL IMPLEMENTATION FOR BASELINE (YEARS 1- 2, UG3 PHASE) AND OF FOLLOW-UP (YEARS 3-4 AND YEARS 5-6, UH3 PHASE) ASSESSMENTS. A MUCH-NEEDED DIETARY SOURCES OF SODIUM STUDY WILL ALSO BE PERFORMED AT BASELINE AND YEARS 5-6 FOLLOW-UP TO TARGET/TRACK SODIUM REDUCTION EFFORTS ACCORDING TO LOCAL CONTEXT AND CULTURE. THE RETAILS SURVEYS OVER THE STUDY PERIOD WILL CAPTURE NOVEL DATA ON PACKAGED, UNPACKAGED, AND INFORMAL RESTAURANT/HAWKER FOOD THROUGH THE INTERNATIONAL FOODSWITCH PROGRAM, WHICH COMBINES A CONSUMER FACING TOOL WITH CROWDSOURCING TO BETTER DEFINE NIGERIA'S FOOD SUPPLY. WE WILL USE THE EXPLORATION, PREPARATION, IMPLEMENTATION AND SUSTAINMENT (EPIS) FRAMEWORK THROUGHOUT BOTH PHASES. THE FORMATIVE RESEARCH PERIOD WILL INCLUDE EXPLORATION AND PREPARATION, WHEN WE WILL PERFORM QUANTITATIVE AND QUALITATIVE MEASURES OF KEY PROCESS INDICATORS, RELEVANT CONTEXTUAL FACTORS INFORMED BY CFIR, AND RELEVANT PROCTOR IMPLEMENTATION OUTCOMES, ACCEPTABILITY, FEASIBILITY AND APPROPRIATENESS. AS IMPLEMENTATION IS STARTED, WE WILL USE THE REACH, EFFECTIVENESS, ADOPTION, IMPLEMENTATION AND MAINTENANCE (RE-AIM) FRAMEWORK, INCLUDING IMPLEMENTATION OUTCOMES (FEASIBILITY, FIDELITY, ADOPTION, ACCEPTABILITY, AND COST) AND CONTEXTUAL FACTORS ASSOCIATED WITH THE IMPLEMENTATION AND SUSTAINMENT PHASES. WE WILL DISSEMINATE OUR FINDING VIA MASS MEDIA ADVOCACY CAMPAIGNS AND WILL EXTEND OUR EXISTING IMPLEMENTATION RESEARCH TRAINING PROGRAM TO STAKEHOLDERS FOR KNOWLEDGE TRANSLATION THROUGH EVIDENCE-INFORMED POLICYMAKING TO OPTIMIZE SUSTAINABILITY. WE WILL HOST MULTISECTORAL STAKEHOLDER MEETINGS TO FACILITATE CROSS-SECTORAL COLLABORATION, DISSEMINATION, AND MULTI-LEVEL POLICY COHERENCE AMONG SECTORS INCLUDE FOOD, HEALTH, TRADE, AND LAW, AMONG OTHERS. THE PROPOSAL BUILDS ON THE TEAM'S EXISTING NHLBI-FUNDED LARGE-SCALE HYPERTENSION CONTROL PROGRAM WITH TEAM MEMBERS FROM UNIVERSITY OF ABUJA, NORTHWESTERN UNIVERSITY, AND THE GEORGE INSTITUTE FOR GLOBAL HEALTH, THE LATTER WHICH IS PERFORMING A PARALLEL, GACD-FUNDED ASSESSMENT IN CHINA WITH SIMILAR METHODS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $669.0k | 9/23/25 | ||
| Not listed | $945.9k | 8/31/24 | ||
| Not listed | $33.1k | 10/24/23 | ||
| Not listed | $954.2k | 8/24/23 | ||
| Not listed | $954.2k | 8/24/23 |